Credit: Getty Images. The resubmitted NDA was in response to a Complete Response Letter issued by the FDA in December 2021. The Food and Drug Administration (FDA) has accepted the resubmitted New Drug ...

More than 15 years ago, Yale's Gail D'Onofrio started studying the effectiveness of sublingual (under-the-tongue) buprenorphine for treatment of opioid use disorder (OUD) in the emergency department.

Compared to patients adherent to monthly injectable buprenorphine, patients on other MOUD (adherent and non-adherent) were 3.5 to 8.1x more likely to return to opioid use. In a separate study, ...

Please provide your email address to receive an email when new articles are posted on . Brixadi is the first long-acting buprenorphine injectable that is available in weekly and monthly doses.

RICHMOND, Va., March 31, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc., (Nasdaq: INDV) today announced findings from a new cost impact model published in The Journal of Current Medical ...

Rapid initiation Protocol: Healthcare providers can now initiate treatment with SUBLOCADE after a single dose of transmucosal buprenorphine and a one-hour observation period to confirm ...

Buprenex (buprenorphine) is a prescription opioid drug that’s used to help manage pain. The drug comes in an intramuscular or intravenous (IV) injection. In severe cases, it can be given as needed ...

A study in client-owned dogs with osteoarthritis demonstrated that a single injection of ALA-1000 effectively mitigates pain and improves functional mobility, with a sustained drug release profile for ...

The US Food and Drug Administration (FDA) has approved extended-release injection buprenorphine (Brixadi, Braeburn Inc) for the treatment of moderate to severe opioid use disorder (OUD). The ...

Credit: Getty Images. Brixadi (buprenorphine) is an investigational, extended-release weekly and monthly subcutaneous injection for moderate to severe opioid use disorder. The Food and Drug ...